Midjourney has ended free trials of its AI image generator citing abuse.
These fake images of the Pope and Donald Trump have gone viral in recent weeks, both were created on Midjourney v5.
Midjourney has ended free trials of its AI image generator citing “extraordinary demand” and “abuse.” Founder David Holz took to the company’s discord channel to announce the news. “Due to a combination of extraordinary demand and trial abuse we are temporarily disabling free trials until we have our next improvements to the system deployed,” Holz wrote on March 28.
It comes after a series of high-profile viral synthetic images swept the internet that the company’s latest model,
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Midjourney ends free trials of its AI image generator due to 'extraordinary' abuse | EngadgetMidjourney has dropped free trials of its AI image generator after users created deepfakes of Trump, the Pope and others..
Read more »
After deepfakes go viral, AI image generator Midjourney stops free trials citing “abuse”After deepfakes go viral, AI image generator Midjourney stops free trials citing 'abuse'
Read more »
Free ride-share in West Dallas; yes, free: Here’s how it works and who benefitsFree rideshare in West Dallas similar to Uber and uses GoPass app.
Read more »
G-Star Raw Releases AI-designed Denim CollectionG-Star Raw is going deeper into the technology space with its latest denim launch.
Read more »
Musk's Brain Implant Company in Search of Human Trials PartnerElon Musk's brain implant company Neuralink has approached one of the biggest US neurosurgery centers as a potential clinical trials partner as it prepares to test its devices on humans once regulators allow for it.
Read more »
Johnson & Johnson halts development of RSV vaccine in midst of late-stage clinical trials | CNNJanssen, the pharmaceutical division of the Johnson & Johnson companies, announced Wednesday that it will scrap development of a vaccine for respiratory syncytial virus, or RSV, in adults.
Read more »